Figure 1

EndoS treatment ameliorates clinical and histological MOG _35-55 -induced EAE. (A) A schematic representation of the experimental setup. (B) MOG_35-55-induced EAE is inhibited in WT mice, but not in B cell-deficient (μMT KO) mice, treated with EndoS; EAE scores were determined daily after disease onset in EndoS-treated mice (triangles; n = 11) and PBS-treated controls (squares; n = 10). Data are presented as mean EAE score ± s.e.m. A significant statistical difference between the two groups of WT mice is observed from peak disease (day 20) to chronic phase (day 30). Data are representative of three individual experiments. (**P < 0.01). (C) Representative images of paraffin-embedded spinal cord sections at peak disease (day 22) of indicated groups stained for hematoxylin and eosin (H&E) or Luxol fast blue/Periodic acid Shiff stain (LFB/PAS) (magnification 200x) are shown. Five sections of spinal cord per mouse (n = 6 for EndoS-treated mice; n = 4 for PBS-treated WT mice) were analyzed, and the number of (D) inflammatory lesions and (E) extent of demyelination per spinal cord section are presented as histograms. Error bars represent the mean ± s.e.m. **P < 0.01 by Student’s t-test.